We are live on ! Find out more
ACM

AIGH Capital Management Portfolio holdings

AUM $733M
1-Year Est. Return 327.32%
This Fund
S&P 500
This Quarter Est. Return
+39%
1 Year Est. Return
+327.32%
3 Year Est. Return
+1,033.66%
5 Year Est. Return
+1,660.59%
10 Year Est. Return
–
AUM
$413M
AUM Growth
+$58.3M
Cap. Flow
-$3.22B
Cap. Flow %
-779.52%
Top 10 Hldgs %
67.54%
Holding
46
New
8
Increased
12
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
KYTX icon
Kyverna Therapeutics
KYTX
+$11.1M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$11M
3
ABEO icon
Abeona Therapeutics
ABEO
+$10.1M
4
BKTI icon
BK Technologies
BKTI
+$8.06M
5
BYRN icon
Byrna Technologies
BYRN
+$7.69M

Top Sells

Rank Stock Value
1
MXL icon
MaxLinear
MXL
+$17.8M
2
LUMN icon
Lumen
LUMN
+$15.6M
3
ZVRA icon
Zevra Therapeutics
ZVRA
+$11.7M
4
APPS icon
Digital Turbine
APPS
+$9.75M
5
PSNL icon
Personalis
PSNL
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 44.17%
2 Technology 34.3%
3 Industrials 3.4%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDK
1
Sandisk
SNDK
$201B
$66.5M 16.09%
280,000
– –
ZM icon
2
CALL
Zoom
ZM
$26.7B
$60.4M 14.62%
+700,000
New +$58.9M
CSTL icon
3
Castle Biosciences
CSTL
$733M
$24.3M 5.88%
624,719
-82,568
-12% -$2.66M
PSNL icon
4
Personalis
PSNL
$1.61B
$23.1M 5.59%
2,900,000
-992,101
-25% -$8.68M
LASR icon
5
nLIGHT
LASR
$3.91B
$22.5M 5.45%
600,103
– –
DAWN
6
DELISTED
Day One Biopharmaceuticals
DAWN
$18.6M 4.49%
1,992,021
+471,529
+31% +$3.94M
VNDA icon
7
Vanda Pharmaceuticals
VNDA
$327M
$17.6M 4.27%
+1,998,431
New +$11M
BKTI icon
8
BK Technologies
BKTI
$307M
$15.8M 3.82%
211,453
+112,444
+114% +$8.06M
DOMO icon
9
Domo
DOMO
$157M
$15.5M 3.75%
1,837,762
+496,244
+37% +$5.83M
ESPR
10
DELISTED
Esperion Therapeutics
ESPR
$14.8M 3.58%
4,000,000
+1,000,000
+33% +$3.23M
KYTX icon
11
Kyverna Therapeutics
KYTX
$453M
$14.1M 3.41%
+1,500,000
New +$11.1M
FENC icon
12
Fennec Pharmaceuticals
FENC
$365M
$12.2M 2.95%
1,581,501
+900,000
+132% +$7.39M
LPTH icon
13
Lightpath Technologies
LPTH
$657M
$11.1M 2.69%
1,030,738
+130,738
+15% +$1.06M
ABEO icon
14
Abeona Therapeutics
ABEO
$399M
$10.5M 2.55%
+2,000,000
New +$10.1M
ZVRA icon
15
CALL
Zevra Therapeutics
ZVRA
$755M
$8.96M 2.17%
1,000,000
-2,221,110
-69% -$21M
IDN icon
16
Intellicheck
IDN
$75.5M
$8.11M 1.96%
+1,213,434
New +$6.85M
LRMR icon
17
Larimar Therapeutics
LRMR
$384M
$7.62M 1.84%
2,000,000
+1,000,000
+100% +$3.89M
ARQ icon
18
Arq
ARQ
$88.4M
$7.43M 1.8%
2,273,092
-306,394
-12% -$1.5M
ARDX icon
19
Ardelyx
ARDX
$1.28B
$6.7M 1.62%
1,150,000
+951,500
+479% +$5.3M
BYRN icon
20
Byrna Technologies
BYRN
$75.8M
$6.63M 1.6%
+394,906
New +$7.69M
PYPD icon
21
PolyPid
PYPD
$103M
$5.83M 1.41%
1,342,972
+277,844
+26% +$1.03M
COYA icon
22
Coya Therapeutics
COYA
$106M
$5.66M 1.37%
975,404
-130,218
-12% -$792K
STX icon
23
CALL
Seagate
STX
$178B
$5.51M 1.33%
20,000
-12,450,132
-100% -$3.23B
TLPH icon
24
Talphera
TLPH
$68.5M
$5.31M 1.29%
4,661,502
+206,957
+5% +$250K
APYX icon
25
Apyx Medical
APYX
$180M
$3.87M 0.94%
+1,104,970
New +$3.85M
1
2

Similar funds

GFI
Global Frontier Investments Charleston, South Carolina $732M AUM 8.6% 1-Year Est. Return
RP
Rice Partnership Honolulu, Hawaii $732M AUM 28.13% 1-Year Est. Return
IA
Intellus Advisors Naples, Florida $732M AUM 29.73% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
GIC
GFI Investment Counsel Toronto, Ontario, Canada $731M AUM 3.86% 1-Year Est. Return
CT
Colonial Trust Spartanburg, South Carolina $735M AUM 18% 1-Year Est. Return
TWP
TFO Wealth Partners Maumee, Ohio $735M AUM 21.07% 1-Year Est. Return
GWS
Glassman Wealth Services Vienna, Virginia $736M AUM 17.99% 1-Year Est. Return

AIGH Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, AIGH Capital Management held 46 positions worth $413M, up 16% from $355M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

AIGH Capital Management withdrew a net $3.22B in Q4 2025, closing 12 positions and reducing 10 holdings. Its most notable exit was MaxLinear, an estimated $17.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 32% a quarter earlier, followed by Technology and Industrials.

Against the trend, AIGH Capital Management opened a new position in Kyverna Therapeutics worth $14.1M.

  • AIGH Capital Management's largest Q4 2025 buy was Kyverna Therapeutics: 1,500,000 shares worth $14.1M.
  • AIGH Capital Management added most to BK Technologies in Q4 2025, an estimated $8.06M increase.
  • AIGH Capital Management's biggest Q4 2025 reduction was Personalis, cutting an estimated $8.68M.
  • AIGH Capital Management fully exited MaxLinear in Q4 2025, selling an estimated $17.8M.
  • AIGH Capital Management's ten largest holdings make up 68% of its $413M portfolio in Q4 2025.
  • AIGH Capital Management opened 8 new positions and closed 12 in Q4 2025.
  • AIGH Capital Management's portfolio value rose 16% quarter-over-quarter to $413M.

Based on AIGH Capital Management's 13F filing for Q4 2025, filed 2 Feb 2026.